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ABSTRACT: The pathophysiological explanation for fatigue, one of the most
common symptoms in sarcoidosis, still has to be elucidated. It was hypothesized that
the presence of fatigue is associated with an acute phase response in sarcoidosis.
A cross-sectional study was performed in 38 sarcoidosis patients. Resting energy
expenditure (REE) was measured in the fasting state by indirect calorimetry using a
ventilated hood and adjusted for fat-free mass (FFM).
Patients with fatigue (n=25) also suffered more frequently from other symptoms,
such as exercise intolerance (p=0.01), the need for sleep (p=0.02) and weight loss (p=
0.01), compared to those without fatigue (n=13). However, no relationship was found
between fatigue and serum angiotensin-converting enzyme (sACE) or lung function
impairment. Patients with fatigue had higher levels of C-reactive protein (CRP)
(11.46.8 mg.mL-1, p<0.0001) and REE adjusted for FFM (33.03.7 kcal.kg FFM-1,
p<0.003) compared to those without fatigue (3.22.2 mg.mL-1; 29.22.8 kcal.kg FFM-1).
Furthermore, REE/FFM was significantly related to CRP (r=0.54, p=0.001).
This study confirms the presence of an acute phase response as indicated by
metabolic derangements and a moderate increase in C-reactive protein levels in sar-
coidosis, particularly in those patients with constitutional symptoms. Future studies
should focus on the clinical relevance and therapeutic implications of these findings.
Eur Respir J 1999; 13: 718±722.
*Dept of Pulmonology, University Hos-
pital Maastricht, Maastricht, the Nether-
lands. **Dept of Psychology, Tilburg
University, The Netherlands. +Dept of
Clinical Chemistry, University Hospital













Received: June 30 1998
Accepted after revision September 22 1998
Sarcoidosis is a multiorgan disorder of unknown origin,
characterized by T-lymphocyte and mononuclear phago-
cyte infiltration in the affected organs, granuloma forma-
tion, and distortion of the normal microarchitecture, which
is probably antigen-driven [1]. The clinical manifestations
of sarcoidosis are largely nonspecific, dependent on the
intensity of the inflammation and organ systems affected,
of which the lung is the most prominent. Patients with
sarcoidosis generally present with symptoms directly relat-
ed to the chest involvement such as coughing, dyspnoea,
particularly with exertion, and chest pain. Furthermore, they
may suffer from nonspecific constitutional complaints such
as fever, weight loss, fatigue, anorexia and malaise [2].
While there is no single test that reflects accurately the
progression of sarcoidosis, medical history, clinical exami-
nation, chest radiographs, lung function tests and serum
angiotensin-converting enzyme (sACE) levels are used to
evaluate and monitor the disease process [2±6]. When fea-
tures of disease activity, for example radiological abnor-
malities, lung function impairment and sACE, become
normal, less specific and otherwise difficult to objectify
symptoms, such as fatigue and general weakness, may per-
sist [5, 7]. Previously, the authors found that sarcoidosis
patients with normal lung function test results demonstra-
ted reduced respiratory muscle strength and endurance
time [8]. Correlations were found between these measures
and the most commonly reported complaint, fatigue, in
addition to impairment in health status. However, no such
relation was demonstrated with sACE levels [8]. Pathog-
nomonic criteria or a "gold standard" for monitoring the
disease activity of sarcoidosis do not exist [2, 4, 5]. There-
fore, a search for other parameters useful in monitoring
disease activity is still of benefit.
Similar to systemic infections, extensive tissue damage
owing to hypersensitivity or autoimmune reactions is
capable of inducing an acute phase response [9]. This acute
phase response is characterized by hypermetabolism and
the elevation of acute phase proteins, such as C-reactive
protein (CRP), which are produced in the liver [9, 10].
Based on the fact that sarcoidosis can be considered an
inflammatory disease together with observations in other
inflammatory conditions, the authors hypothesized the pre-
sence of metabolic alterations and a hepatic acute phase
response in sarcoidosis patients associated with constitu-
tional symptoms such as fatigue. Furthermore, the impact
of fatigue on clinical parameters used to assess disease
activity in sarcoidosis was evaluated.
Materials and methods
Subjects
Thirty-eight outpatients with newly suspected untreated
sarcoidosis were included in this study. The diagnosis ofFor editorial comments see page 713.
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sarcoidosis was based on consistent clinical features,
together with bronchoalveolar lavage (BAL) fluid analysis
results [6]. Moreover, all patients had a biopsy confirma-
tion of sarcoidosis. The clinical symptoms of the respective
patients varied from none (sarcoidosis detected on routine
chest radiography) to more or less severe respiratory symp-
toms or erythema nodosum and arthralgia (i.e. LoÈfgren's
syndrome). None of the subjects participating had any
significant medical history or comorbidity. Moreover, cu-
tures of the BAL fluid samples obtained were all negative.
For information about the presence of constitutional
symptoms, the participating patients completed a symptom
questionnaire [11] under the supervision of a study as-
sistant, to ensure correct answers and to avoid the omission
of data. Moreover, the patient's quality of life (QoL) was
evaluated using a broad-ranging QoL instrument, the World
Health Organization QoL assessment instrument (WHO-
QoL-100; Dutch version) [12]. The WHOQoL-100 con-
sists of 100 items assessing 24 facets of QoL within six
domains and a global evaluative general QoL facet. To
measure and qualify fatigue in the present study, only the
energy and fatigue facet from the physical health domain
was evaluated. Higher scores represent a better QoL for
this facet [12]. Written informed consent was obtained
from all subjects.
Serological measurements
At the time of the initial diagnosis, sACE and serum
were assessed. ACE was measured with a colorimetric
method using a test kit from Fujirebio Inc. (Tokyo, Japan).
sACE acts upon the substrate p-hydroxybenzoyl-glycyl-L-
histidyl-L-leucine and separates p-hydroxybenzoyl-glycine.
Hippuricase reacts with and breaks down p-hydroxyben-
zoyl-glycine into p-hydroxybenzoic acid and glycine.
Quinoneimine dye is produced by oxidation and con-
densation of the p-hydroxybenzoic acid and 4-aminoanti-
pyrine using sodium metaperiodate (NaIO4). Finally, the
concentration of quinoneimine dye is quantitatively mea-
sured at its maximum absorbance of 505 nm to evaluate the
activity of ACE. The reference normal range under this test
method is 9±25 U.L-1.
CRP was measured using a turbidimetric method per-
formed using the Beckman synchron CX-7 system (kit
465231; Mijdrecht, the Netherlands). In this test, CRP
combines with a specific antibody to form insoluble anti-
gen±antibody complexes. The detection limit for CRP us-
ing the turbimetry assay was 2 mg.mL-1, with a normal
range of 2±9 mg.mL-1.
Lung function tests and respiratory muscle strength
Lung function measurements included forced expiratory
volume in one second (FEV1) and inspiratory vital capa-
city (IVC) measured with a pneumotachograph. The trans-
fer factor of the lung for carbon monoxide (TL,CO) was
measured by the single-breath method (Masterlab; Jaeger,
WuÈrzburg, Germany). Values were expressed as a percen-
tage of those predicted [13].
Inspiratory and expiratory muscle strength were as-
sessed by measuring maximal respiratory mouth pressures
using the method of BLACK and HYATT [14]. The maximal
inspiratory mouth pressure (PI,max) was measured at
residual volume (RV), and the maximal expiratory mouth
pressure (PE,max) was measured at total lung capacity
(TLC). The equipment used was a pressure transducer
(model MP 45-30; Validyne Engineering Corp., North-
ridge, CA, USA). All signals were recorded on a strip chart
(type BD 31; Kipp & Zonen, Delft, the Netherlands). A
needle was placed in the proximal end of the mouthpiece to
ensure that efforts were performed with an open glottis. At
least five manoeuvres were performed, until the three
highest values were within 5% of each other. All subjects
were seated in an upright position and were wearing a
noseclip while performing the tests, and the same in-
structions were given to each subject by an investigator.
Values are expressed as absolute values and as percentages
of predicted values according to WILSON et al. [15].
Chest radiographs
Chest radiographs were performed in the posterior±
anterior and lateral projections, and were classified by a
single experienced reader, blinded to the patient's clinical
history, in a standard manner according to the radiographic
stage (0±IV) [16].
Metabolic measures
Body composition was measured by single-frequency
bioelectrical impedance analysis (RJL Systems, Detroit,
MI, USA) in the supine position on the right side. Fat-free
mass (FFM) was calculated from height2/resistance and
body weight using the Lukaski formula. In order to assess
the degree of functional tissue depletion, FFM was adjust-
ed for body size by calculating the FFM index (FFM/
height2 (kg.m-2)). Fat mass was calculated by subtracting
FFM from body weight.
Resting energy expenditure (REE) was measured after
an overnight fast under standardized conditions [17] by
means of indirect calorimetry using a ventilated hood (Ox-
ycon beta1, Mijnhardt, Bunnik, the Netherlands). REE
was adjusted for FFM and sex by analysis of covariance
[18].
Statistical analysis
Results are presented as meanSD unless stated other-
wise. Pearson's and, if appropriate, partial (sex was partiall-
ed out) correlation coefficients (r) were computed to assess
the mutual relationship between the various tests. The Chi-
squared test was used for nominal variables. To assess sex
differences between the studied groups, Student's t-test
was used. To examine differences between the sarcoidosis
groups with and without fatigue with respect to medical
data, an analysis of variance was applied with sex as
covariate. Analyses of variance (sex as covariate) were also
used to compare patients with and without exercise in-
tolerance and patients with and without weight loss with
regard to REE adjusted for FFM. In all tests, a p-value of
<0.05 was considered to be statistically significant. All
analyses were performed using the Statistical Package for
Social Science (SSPS) for Windows (SPSS, Chicago, IL,
USA).
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Results
The demographic and clinical characteristics, laboratory
test results, lung function test results, and body composi-
tion of the patients suffering from sarcoidosis studied
(n=38) are summarized in table 1. The patient population
was divided into two groups, according to the presence of
fatigue as assessed by WHOQoL-100. Group I (n=13)
consisted of patients who did not suffer from fatigue
while group II (n=25) consisted of sarcoidosis patients
who suffered from fatigue. Both groups differed with
respect to other constitutional symptoms as well (fig. 1).
Patients with fatigue suffered more frequent dyspnoea
(x2 (1)=6.3, p=0.01), exercise intolerance (x2 (1)=6.9, p=
0.009), muscle pain (x2 (1)=10.2, p=0.001), eye problems
(x2 (1)=4.1, p=0.04) and the need for sleep (x2 (1)=3.9,
p= 0.05) compared to patients without fatigue. These res-
pective groups did not differ with respect to age, smoking
history, use of corticosteroids, radiographic stage, sACE
levels or lung function test results.
Group II patients, with fatigue, reported more weight
loss (number of kg, F(1)=7.9, p=0.02), had a higher serum
CRP level compared to group I (F (1)=15.4, p<0.0001), a
higher REE (F(1)=4.3, p=0.05), a higher REE adjusted for
FFM (F(1)=9.5, p=0.004) as well as fat mass expressed as
a percentage of weight (F(1)=13.4, p=0.001) and body
mass index (BMI) (F(1)=4.1, p=0.05) (table 1). No dif-
ference was demonstrated in FFM. However, FFM calcu-
lated as a percentage of body weight was lower in the
group with fatigue (F(1)=10.5, p=0.0003). Furthermore,
the PI,max (F(1)=5.4, p=0.04) appeared to be more im-
paired in group II. Moreover, REE divided by FFM was
significantly associated with CRP levels (r=0.54, p=0.001;
fig. 2), and significantly higher in patients suffering from
weight loss (F(1)=5.2, p=0.03) or exercise intolerance
(F(1)=12.3, p=0.001). Exercise intolerance also appeared
to be related to increased body temperature (x2 (1)=5.7,
p=0.02). The radiographic stage was positively related to
REE divided by FFM (r=0.39, p=0.02). However, no
relationship was found between either the radiographic
stage and lung-function test results or with sACE or any
other laboratory finding listed in table 1.
Discussion
This study is the first to describe a relationship between
one of the most common symptoms in sarcoidosis, i.e.
fatigue and the presence of an acute phase response,
evidenced by hypermetabolism and a limited increase in
the serum CRP level. Moreover, patients suffering from
fatigue were characterized by a different body composition
compared to those patients not suffering from fatigue. No






















































































Fig. 1. ± Most relevant reported symptoms in sarcoidosis. Group I (h,
n=13): patients without fatigue, and group II (u, n=25): patients suf-
fering from fatigue. *: p<0.05 group I versus group II.
Table 1. ± Summary of demographic, clinical, laboratory
and lung function test results, as well as metabolic chara-
cteristics of the patients with sarcoidosis
Group I Group II Total
population
Demographic, clinical and laboratory characteristics
n 13 25 38
Sex M/F 8/5 14/11 22/16
Age yrs 40.210.7 40.012.1 40.111.5
Smoking yes/no 3/10 4/21 7/31
Radiographic stage
0 1 1 2
I 4 7 11
II 8 10 18
III 0 6 6
IV 0 1 1
Calcium mmol.L-1 2.470.07 2.430.08 2.440.08
CRP mg.mL-1 3.22.2 11.46.8** 8.76.9
sACE U.L-1 24.99.8 26.111.5 25.710.8
ESR mm.h-1 6.810.0 12.110.7 10.310.7
Lung function test results
FEV1 % pred 85.620.9 88.318.4 87.419.1
FVC % pred 100.623.8 92.721.9 95.522.6
TL,CO % pred 89.122.4 87.821.7 88.221.6
PI,max cmH2O -113.023.3 -91.225.1* -97.826.3
PE,max cmH2O 117.426.6 100.022.3* 105.324.6
Metabolic characteristics
BMI kg.m-2 24.02.5 26.03.5+ 25.43.3
FFM kg 56.09.5 52.611.1 53.810.6
FFM index kg.m-2 18.01.9 17.22.8 17.52.5
FFM % weight 75.45.1 66.68.6** 69.58.6
Fat mass kg 18.13.8 25.98.1* 23.27.8
Fat mass % weight 24.65.1 33.58.4** 30.78.5




Data are expressed as number or meanSD. Group I: patients
presenting without fatigue; and group II: patients suffering from
fatigue. M: male; F: female; CRP: C-reactive protein (reference
range 2±9 mg.mL-1); sACE: serum angiotensin-converting
enzyme (reference range 9±25 U.L-1); ESR: erythrocyte sedi-
mentation rate (reference range 0±12 mm.h-1); FEV1: forced
expiratory volume in one second; FVC: forced vital capacity;
TL,CO: transfer factor of the lung for carbon monoxide; PI,max:
maximal inspiratory mouth pressure measured at residual vol-
ume; PE,max: maximal expiratory mouth pressure measured at
total lung capacity; BMI; body mass index; FFM: fat-free mass;
REE: resting energy expenditure; Reference range for calcium
2.1±2.6 mmol.L-1. +: p=0.05; *: p<0.05; **: p<0.01.
720 M. DRENT ET AL.
used parameters for monitoring disease activity in sar-
coidosis, such as the sACE level, radiographic findings and
lung function tests. Only a negative relationship between
the radiographic stage and the FFM was demonstrated.
Clearly, there is a wide spectrum of tissue inflammation
and organ dysfunction within, as well as between, each
radiographic stage. KARETZKY and MCDONOUGH [19] found
that the magnitude of functional impairment may vary
widely from the apparent histopathological involvement,
as reflected by chest radiography results and lung volumes.
There is little true incidence data in the literature regarding
metabolic alterations in patients with sarcoidosis. Only one
report, including 12 patients within various interstitial lung
diseases (ILD), of which only three were suffering from
sarcoidosis, demonstrated the presence of an elevated REE
[20].
Increased CRP production is a nonspecific response to
most forms of tissue inflammation [21, 22]. Hepatocytes
have been identified as the site of origin of acute phase
proteins such as CRP. Thus, the liver plays an important
role in the acute phase response [10, 23]. The CRP res-
ponse (although rather minor) was present in the majority
of patients and appeared indicative of the inflammatory
activity of sarcoidosis. Similar responses (resulting in a
slightly elevated or normal CRP) are reported in inflam-
matory disorders such as systemic lupus erythematosus,
Crohn's disease, and ulcerative colitis [24]. In contrast, an
intercurrent microbial infection provokes a major CRP
response [10]. To date, HIND et al. [25] have found, in their
study population, an increased CRP in two of nine patients
with active sarcoidosis (22.2%), but in none of five
inactive sarcoidosis patients.
Most clinical manifestations of sarcoidosis are second-
ary to the direct effect of the accumulation of activated
immunocompetent cells in the tissues involved, notably
helper T-lymphocytes and macrophages [1, 2, 5, 9, 26, 27].
The activation of cells of the monocyte/macrophage line-
age is compartmentalized. Alveolar macrophages have been
identified as releasing tumour necrosis factor (TNF)-a,
interleukin (IL)-1, and prostaglandin E2 spontaneously in
the course of sarcoidosis, whereas the corresponding cells
of the peripheral blood are quiescent [1, 5, 26]. In the
present study, cytokine levels were not measured but, as
would be expected, a significant relationship between the
elevated CRP levels and resting metabolic rate was found.
The clinical significance of this relationship was indicated
by the fact that REE and CRP were significantly higher in
patients suffering from fatigue. In line with this, the authors
have previously found that the serum CRP level was
related to fatigue in patients with an autoimmune disease,
rheumatoid arthritis (RA). Patients suffering from RA with
a high serum CRP level were reported to be significantly
more impaired by fatigue (assessed by the WHOQoL-100
facet energy and fatigue [12]) compared to those with a
normal serum CRP level (unpublished data). In some
hypermetabolic patients with chronic obstructive pulmon-
ary disease [17], an increased resting metabolic rate seems
to be related to the level of systemic inflammation.
Furthermore, patients with fatigue were characterized by a
significantly higher fat mass, whereas FFM as a percentage
of body weight was significantly decreased in this group.
These body compositional changes suggest a preferential
loss of FFM in the latter group. The findings of the present
study could indicate a catabolic response in a subgroup of
sarcoidosis patients, which may be consistent with the
hypothesis that during an acute phase response cytokines
redirect host protein metabolism away from peripheral
tissue such as muscle and towards the liver. The higher fat
mass in the subgroup of sarcoidosis patients suffering from
fatigue, however, could in view of other symptoms exper-
ienced also be associated with a disease-related impair-
ment of the functional capacity [26, 28]. Moreover, under
those circumstances, one might also expect a higher body
weight and perhaps weight gain in the patients with symp-
toms, whereas, on the contrary, weight loss was reported
more often. Nevertheless, a decreased FFM in turn may
affect respiratory muscle strength, which, in the present
study as well as in a previous study, was indeed found to be
significantly reduced [8]. Furthermore, it was previously
reported that patients with sarcoidosis were limited in
physical functioning [8].
It has generally been assumed that the marked loss of
body proteins resulting in a loss of body mass (initiated by
TNF-a and leukocyte pyrogen or IL-1 and mediated by
prostaglandin E2) occurs primarily in the skeletal muscle,
which constitutes the major protein reserve of the organism
[23]. Net protein breakdown in muscle can also provide
amino acids for synthesis of acute phase proteins by the
liver and for the synthesis of immunoglobulins, commonly
increased in sarcoidosis [2, 4, 23]. Leukocyte pyrogen also
causes induction of acute phase proteins and enhancement
of lymphocyte proliferation [23, 26]. Moreover, it is well
established that prostaglandin E2 is a very potent stimulator
of peripheral pain receptors and hyperalgia [23]. In
immune disorders such as sarcoidosis and RA, immune-
derived cytokines initiate an acute phase response, which is
also characterized by fever, inactivity, muscle pain, fatigue,
anorexia, and catabolism [23, 29, 30]. An appreciation of
the processes of the acute phase reaction is likely to be of
clinical relevance. For example, the recent demonstration
that muscle breakdown, like fever, is brought about by IL-1
via an intermediate prostaglandin step, suggests that
antiprostaglandin agents may not only cause defervescence
but might also help to prevent muscle breakdown [10].
Therefore, administration of nonsteroidal anti-inflamma-
tory drugs, as an alternative to steroids, might be of benefit
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Fig. 2. ± Relationship between resting energy expenditure (REE) in
kcal adjusted for the fat free mass (FFM; kg) and C-reactive protein
(r=0.54, p=0.001).
721FATIGUE ASSOCIATED WITH HYPERMETABOLISM IN SARCOIDOSIS
in the treatment of sarcoidosis as it has been suggested that
these drugs decrease rates of muscle proteolysis [3, 5, 23].
Future studies are needed to evaluate this suggestion.
In conclusion, this study indicates that an acute phase
response, as evidenced by metabolic derangements and a
moderate increase in the serum C-reactive protein level, is
involved in sarcoidosis. The resting energy expenditure
and serum C-reactive protein level appeared to quantify
and characterize the constitutional impairment and inflam-
mation in patients with sarcoidosis. In addition, constitu-
tional symptoms, e.g. fatigue, that are otherwise difficult to
objectify accurately, were found to be related to the resting
energy expenditure as well as the serum C-reactive protein
level. Therefore, an assessment of the serum C-reactive
protein level and resting energy expenditure adjusted for
body composition may be useful in the management of
sarcoidosis. Further investigations, including cytokine de-
termination, are needed to determine the clinical im-
portance of the acute phase response associated with
inflammation and related symptoms, such as fatigue, in
sarcoidosis.
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